Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery

Por van Veelen, M L C, Avezaat, C, Kros, J, van Putten, W, Vecht, C.
Publicado em 1998

The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients.

Por Vecht, C J, Avezaat, C J, van Putten, W L, Eijkenboom, W M, Stefanko, S Z
Publicado em 1990

Heterogeneous X inactivation in trophoblastic cells of human full-term female placentas.

Por Looijenga, L H, Gillis, A J, Verkerk, A J, van Putten, W L, Oosterhuis, J W
Publicado em 1999

Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.

Por van der Gaast, A., van Putten, W. L., Oosterom, R., Cozijnsen, M., Hoekstra, R., Splinter, T. A.
Publicado em 1991

Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.

Por Peters, W. H., Roelofs, H. M., van Putten, W. L., Jansen, J. B., Klijn, J. G., Foekens, J. A.
Publicado em 1993

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Por Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., Klijn, J. G.
Publicado em 1994

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.

Por Romain, S., Chinot, O., Klijn, J. G., van Putten, W. L., Guirou, O., Look, M., Martin, P. M., Foekens, J. A.
Publicado em 1994

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

Por Hilkens, P. H., Pronk, L. C., Verweij, J., Vecht, C. J., van Putten, W. L., van den Bent, M. J.
Publicado em 1997

Immediate and intermediate results of stent therapy for aortic coarctation

Por Honing-Hemmers, A.M., van Putten, W.K., Gewillig, M., Mast, G., Talsma, M., Tanke, R., de Wolff, D., Sreeram, N.
Publicado em 2003

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado em 2002

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cance...

Por Bontenbal, M., Foekens, J. A., Lamberts, S. W., de Jong, F. H., van Putten, W. L., Braun, H. J., Burghouts, J. T., van der Linden, G. H., Klijn, J. G.
Publicado em 1998

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

Por de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Publicado em 1999

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Por Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publicado no Br J Cancer (2018)